New Delhi, Sep 26 (PTI) Diagnostic services provider Dr Lal PathLabs Ltd on Saturday said its wholly owned subsidiary, Dr Lal PathLabs FZCO, Dubai, has completed the acquisition of an 80 per cent stak ...

Dr. Lal PathLabs to acquire 70% stake in SN Genelab, strengthening its genomics expertise and expanding advanced diagnostic ...

Founded by Dr Salil Vaniawala in December 2013, SN Genelab is ‘currently a leader in genomics testing in India’, according to Nomura.

Emkay Global Financial is bullish on Dr Lal Pathlabs has recommended buy rating on the stock with a target price of Rs 2100 ...

The ₹168 crore acquisition of a 70 per cent stake in SN Genelab is expected to strengthen Dr Lal's genomics expertise and ...

After a long stretch of stock underperformance, domestic brokerage Kotak Institutional Equities stated in its most recent report that it has double upgraded Dr Lal Pathlabs from Sell to Add with an ...

The board declared an interim dividend of ₹5 per equity share, or 50% of the face value of ₹10 each, for FY27. The record date for determining eligible shareholders has been fixed as July 30, with the ...

Dr Lal PathLabs Ltd is set to acquire a 70% stake in SN Genelab for around Rs 168 crore, expanding its capabilities in ...

Dr. Lal PathLabs Limited (NSEI:LALPATHLAB) agreed to acquire 70% stake in Sn Genelab Private Limited for INR 2.0 billion on September 24, 2026. A cash consideration of INR 1.68 billion will be paid by ...

Vandana Lal is the Executive Director at Dr Lal PathLabs. The company was started in 1949 by the late SK Lal – He was a Junior Doctor in the British Army. He went to Pune to study at the Armed Forces ...

Dr Lal PathLabs’ Dubai subsidiary has acquired an 80% stake in Ghana’s Sunshine Healthcare, making it a step-down subsidiary ...

Sunshine Healthcare was incorporated in Ghana in September 2010 and is engaged in healthcare and diagnostic services. The ...